Gelonghui, April 3 | Kang Feng Bio-B (06922.HK) announced that the company has applied to the Stock Exchange Listing Committee to approve 29,341,981 H shares of the company, that is, the maximum number of unlisted shares of the company to be converted, listed and traded under the conversion and listing. The Company is pleased to announce that on April 3, 2024, the Stock Exchange has granted listing approval, which is subject to all other conditions for conversion and listing before it can be implemented.
康沣生物-B(06922.HK)：联交所授出上市批准实施H股全流通
Kang Feng Bio-B (06922.HK): The Stock Exchange granted listing approval to implement full circulation of H shares
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.